Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

American stocks have crashed this year as concerns about Donald Trump tariffs rose. The top blue-chip indices like the Dow ...

Vanguard Health Care ETF (VHT) is rated a hold due to high valuations and low profitability of top holdings despite strong ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational ...